Background
Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of the adrenal medulla and extra-adrenal sympathetic chromaffin tissues; their anatomical and functional imaging are critical to guiding treatment decisions. This study aimed to compare the sensitivity and specificity of 
Methods
A total of 216 patients (106 men, 110 women, aged 45.2 ± 14.9 years) with suspected PPGL underwent CT or MRI, 18 F-FDG PET/CT, and 123 I-MIBG SPECT/CT. Sensitivity and specificity were measured as endpoints and compared by the McNemar test, using two-sided P values only.
Results
Sixty (28%) of patients had nonmetastatic PPGL, 95 (44%) had metastatic PPGL, and 61 (28%) were PPGL negative. For nonmetastatic tumors, the sensitivity of F-FDG vs CT/MRI: difference = 18.9%, 95% CI = 9.4% to 28.3%, P < .001). The specificity was 90.2% for 18 F-FDG, 91.8% for 123 I-MIBG, and 90.2% for CT/MRI. 18 F-FDG uptake was higher in succinate dehydrogenase complex-and von Hippel-Lindau syndrome-related tumors than in multiple endocrine neoplasia type 2 (MEN2) related tumors. For metastases, sensitivity was greater for I-MIBG: difference = 24.4%, 95% CI = 11.3% to 31.6%, P < .001). For bone metastases, 18 F-FDG was more sensitive than CT/MRI (sensitivity of 18 F-FDG = 93.7%; of CT/MRI = 76.7%; difference = 17.0%, 95% CI = 4.9% to 28.5%, P = .013).
Conclusions
Compared with 123 I-MIBG SPECT and CT/MRI, both considered gold standards for PPGL imaging, metastases were better detected by 18 F-FDG PET. 18 F-FDG PET provides a high specificity in patients with a biochemically established diagnosis of PPGL.
used with radiopharmaceuticals such as 6-[ F-FDG) has not previously been considered to be a first-line functional imaging agent for PPGL, even though it has been used this way for other tumors (9) , possibly because there is a concern that it may accumulate nonspecifically and provide low sensitivity for benign PPGL. The degree of 18 F-FDG uptake mirrors glucose uptake and metabolism in various tumors (10) . In malignant PPGL and especially in SDHB-related PPGL, metastases are more accurately detected by 18 F-fluorodeoxyglucose positron emission tomography with computed tomography ( 18 F-FDG PET/CT) than by 123 I-MIBG SPECT (8, 11, 12) . Prominent 18 F-FDG uptake by SDHB-related metastases has been suggested to be a hallmark of altered glucose metabolism related to genotype-specific tumor cell biology (13) . 18 F-FDG PET/CT has also been successfully applied in the localization of primary nonmetastatic PPGL, yielding a sensitivity similar to 123 I-MIBG (8) . Therefore, 18 F-FDG has the potential to be useful in PPGL imaging, not only for detection of metastases but also as a tool for functional characterization that identifies tumors with a high metabolic rate and high metastatic potential.
The aims of the this study were 1) to establish the sensitivity and specificity of 18 F-FDG PET for the localization of various genetically-derived nonmetastatic and metastatic PPGLs, 2) to provide a strategy for optimal staging of PPGL and HNPGL by comparing 18 F-FDG PET with the standard imaging techniques (CT, MRI, 123 I-MIBG SPECT), and 3) to investigate whether functional imaging using 18 F-FDG PET might provide clues for a genetic diagnosis underlying PPGL.
Methods

Patients
Between 2003 and 2010, we prospectively studied 216 consecutive patients (106 men and 110 women, aged [mean ± SD] 45.2 ± 14.9 years), who underwent 18 F-FDG scanning as part of their evaluation for suspected PPGL. All patients were investigated at a single center, the National Institutes of Health. The final diagnosis was based on biochemical findings, imaging results, and clinical follow-up. Among the 216 patients, there were 60 (28%) patients with one or multiple foci of nonmetastatic PPGL, 95 (44%) patients with metastatic PPGL, and 61 (28%) patients without evidence of PPGL after detailed evaluation. Metastatic PPGL was defined by the presence of metastatic lesions at sites where chromaffin tissue is normally absent.
PPGL-negative patients had been referred for one or more of the following reasons: 1) symptoms and signs highly suggestive of PPGL; 2) adrenal incidentaloma; 3) a predisposing hereditary disorder associated with the presence of PPGL, including proven mutation carriers and patients with a positive family history and typical signs and symptoms of catecholamine excess; or 4) evaluation for recurrent disease. PPGL was ruled out by normal plasma metanephrine levels, imaging studies, and close clinical follow-up. Patient characteristics are listed in Table 1 and Supplementary  Tables 1-3 (available online) .
There were 66 patients with germline SDHB mutations, 12 with SDHD mutations, and 10 with RET-related MEN2, four patients with VHL syndrome, and one with NF1 mutation. Genetic testing included gene sequencing of SDHB, SDHD, RET, and VHL and assessment of large gene rearrangements of SDHB and SDHD. Patients were not tested for mutations in the recently described genes SDHA (14) , SDHAF2 (15) , and TNEM127 (16) . Imaging results of 51 patients were also included in a previous report that focused on 18 F-FDOPA PET (8) . The protocol (00-CH-0093) was approved by the Institutional Review Board of the Eunice Kennedy Shriver National Institutes of Child Health and Development, National Institutes of Health. All patients provided written informed consent.
Functional Imaging
All functional imaging studies were performed at a single center, the Department of Nuclear Medicine of the National Institutes of Health in Bethesda, MD. Cameras and radiopharmacy equipment were subject to frequent quality control according to institutional standards and protocols. 18 F-FDG PET(/CT) and 123 I-MIBG SPECT(/CT) were performed as described previously (11, 17) . The initial six patients underwent 18 F-FDG PET just before the implementation of PET/CT in our protocol early in 2003. Since then, all PET/CT studies have been performed on the same instrument (GE Discovery ST, GE Healthcare, Chalfont St. Gilles, United Kingdom), using the same protocol (11, 17 
Limitations
The sample size of patients with hereditary nonmetastatic PPGLs and HNPGL was relatively small. Further studies are warranted to assess the full impact of genotypes on functional imaging results.
From the Editors
SPECT/CT instead of SPECT alone was performed in 40 (23.1%) of 173 MIBG scans when the technology became available in 2009. Camera-wise whole-body planar and SPECT-only images were done on a variety of cameras-either a three-headed (Tronix, Meditronix, New Delhi, India) camera or one of our various two-headed gamma cameras (either Siemens, Munich, Germany or Phillips/Adac, Milpitas, CA).
123 I-MIBG scans were performed within 2 weeks of the 18 F-FDG scans in random order, with the exception of five 123 I-MIBG scans that were performed within 2-6 weeks.
123 I-MIBG scans were performed in 55 patients (92%) with nonmetastatic PPGL, in 77 patients (81%) with metastatic PPGL, and in 41 patients (67%) without PPGL.
CT and MRI
All anatomical imaging studies were performed at a single center, the Department of Radiology of the National Institutes of Health in Bethesda, MD. CT scans were performed using LightSpeed Ultra, LightSpeed QX/i (General Electric Healthcare Technologies, Waukesha, WI) and Mx8000 IDT (Philips Medical Systems, Andover, MA) scanners. Section thickness was 2-2.5 mm in the neck and 5 mm through the chest, abdomen, and pelvis. Studies were performed with a rapid infusion of nonionic water soluble contrast agent, as well as oral contrast material.
MRI scans were obtained using 1.5 or 3 T scanners (General Electric Healthcare Technologies and Philips Medical Systems). Image thickness was 5 mm for neck studies and 5-8 mm for other body regions. Studies included injection of a gadolinium-DTPA contrast agent, using fat-suppressed T1-weighted gradient-echo imaging, generally in both axial and coronal planes.
The following body regions were imaged by CT and/or MRI: neck, chest, abdomen, and pelvis in 189 patients; chest, abdomen, and pelvis in 12 patients; neck, abdomen, and pelvis in two patients; neck and abdomen in three patients; neck and pelvis in one patient; abdomen only in three patients; and neck only in two patients. 
Analysis of Data
CT and MRI scans were read by radiologists as part of the clinical routine. Lesions that were "typical" or "highly suspicious" for PPGL were considered positive. 18 F-FDG and 123 I-MIBG scans were read by two nuclear medicine physicians (C. C. Chen and J. A. Carrasquillo) who were blinded to the results of all other imaging studies. Whenever there were discrepancies between the two reports, a consensus reading was performed. Focal areas of abnormal uptake not corresponding to normal physiological sites of accumulation for each of the tracers were considered as lesions. Lesions were graded on a scale of 1-5 (1 = not PPGL, 2 = doubtful, 3 = equivocal, 4 = probable, 5 = definite PPGL). Only lesions with scores of 4 and 5 were counted as positive findings.
HNPGLs were analyzed separately from sympathetic PPGL because they appear to have very different functional imaging properties (18) . Data from patients with HNPGLs were included only if data from an MRI specifically targeted at HNPGL were available as a standard. Without MRI imaging, head and neck lesions seen by 18 F-FDG PET/CT were not scored. For calculations of sensitivity, two different standards were used. For patients with primary nonmetastatic PPGL, histopathologically confirmed PPGLs served as reference. For metastatic PPGL, sensitivity was calculated in reference to lesions detected by any imaging in the following locations: 1) retroperitoneum or mediastinum, 2) bone, 3) liver, and 4) lungs. Thus, each region was scored as tumor positive or negative (region-based sensitivity). Patients with PPGL-negative adrenal glands with an abnormal appearance on CT or MRI (eg, other adrenal tumors) were excluded from the analysis. Maximum SUVs were determined in manually drawn regions of interest over adrenal PPGLs and normal adrenal glands, as delineated by CT. SUV was not calculated for right adrenal glands if there was difficulty separating it from physiological uptake in the liver. Liver-normalized SUVs were calculated as PPGL and adrenal gland maximum SUVs divided by corresponding liver mean SUVs. Regions of interest were drawn in four consecutive slices in the upper central liver to obtain mean liver SUVs.
Statistical Analysis
Results are given as means with 95% confidence intervals (CIs) unless stated otherwise. The McNemar test was used to compare sensitivities and specificities between different imaging modalities. To compare sensitivities of a particular imaging modality between subgroups of patients, that is, comparison of independent observations, a Fisher exact test was used. For the comparison of different imaging modalities within subgroups (paired observations), we used the McNemar test. For comparison of SUVs of hereditary nonepinephrine-producing tumors and other tumors, analysis of variance and post hoc analysis using the Tukey-Kramer test were performed (19) . A two-sided P less than .05 was considered to be statistically significant. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS for
Results
Nonmetastatic PPGL
Among 60 patients, 69 nonmetastatic PPGLs were histopathologically identified, of which 53 were adrenal and 16 extra-adrenal in location (Table 1 and Supplementary Table 1 Table 1 ). Clinical and biochemical follow-up at 1 and 4 years after unilateral PPGL resection, respectively, showed no evidence of disease in these two patients. In one patient, 18 F-FDG showed a lung lesion (sporadic, F54; Table 1), which was subsequently found to be non-small cell lung cancer. The lesion was also visible on CT/MRI. Six 18 F-FDG scans demonstrated uptake in brown fat.
The sensitivity of I-MIBG: 79.6% vs 60%). Also, functional imaging results were independent of biochemical phenotype that is, epinephrine ± norepinephrine-producing vs norepinephrine-only producing (data not shown). (Table 4) .
Metastatic PPGL
PPGL Ruled Out
In the 61 patients in whom PPGL was ruled out, several falsepositive lesions were found by imaging (Supplementary Table 3 , available online). After exclusion of low enhancing adrenal nodules with an "adenoma-like" appearance according to the radiologists, the specificity of CT/MRI was 90.2% (six false-positive scans). If all adrenal nodules on CT/MRI were included, the specificity decreased to 70.5% (18 false-positive scans). The specificity of 18 F-FDG PET was 90.2% (six false-positive scans) and for 123 I-MIBG, it was 91.8% (five false-positive scans). Among the six "false-positive" lesions on 18 F-FDG PET, three were subsequently identified as left renal cell carcinoma (SDHB, M62; Supplementary Table 5 , available online), gastrointestinal stromal tumor (SDHB, M72), and left breast ductal carcinoma (sporadic, F57). The first two lesions were also visible on CT/MRI but were not considered as PPGL by the radiologists. On 18 F-FDG, brown fat was seen in three patients. The false-positives seen with 123 I-MIBG scintigraphy were all due to visualization of presumably normal adrenal glands.
Head and Neck Paraganglioma
A total of 26 HNPGLs were found on CT/MRI in 19 patients (Supplementary Table 6 , available online). I-MIBG = 52% [11/21] ; difference = 33%, 95% CI = 8.6% to 53.0%, P = .021; two-sided McNemar test).
F-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography Standardized Uptake Values
SUVs were statistically significantly higher (P < .001) for adrenal PPGL (5.0 ± 5.5) and extra-adrenal PPGL (8.5 ± 5.5) than for normal adrenal glands (1.6 ± 0.8) (Figure 2 ). There was, however, considerable overlap between the groups. Liver-normalized SUVs showed similar differences: adrenal PPGL, 2.84 ± 3.70 (range = 0.47-17.3); extra-adrenal PPGL, 5.21 ± 3.23; normal adrenal glands of patients without PPGL, 0.84 ± 0.26.
A receiver operating curve was constructed from maximum SUVs of adrenal PPGLs and normal adrenals in patients with nonmetastatic PPGL. The area under curve was 0.921 ( Figure 3) . To provide 100% sensitivity, the upper reference for a normal SUV was established at 1.1 (the minimum value for adrenal PPGL), resulting in a specificity of 73%. To provide 100% specificity, the upper reference for normal was established at 4.6 (the F-FDG was false negative in five patients (5.3%) and CT/MRI in 11 (11.7%).
Sensitivities were compared between 52 SDH patients (47 of whom had SDHB mutations and five of whom had SDHD maximum value for PPGL-negative normal adrenals), resulting in a sensitivity of 82%.
The distribution of SUVs in nonmetastatic PPGLs across hereditary and sporadic tumors is shown in Figure 4 . The maximum SUVs for hereditary non-epinephrine-producing tumors (SDHB, SDHD, VHL) was statistically significantly higher (14.3 ± 6.3, P < .05) than for hereditary epinephrine-producing tumors (MEN2, NF1: 3.1 ± 1.5), sporadic non-epinephrine-producing tumors (7.0 ± 6.0) and sporadic epinephrine-producing tumors (3.8 ± 1.6).
Linear regression analysis revealed a statistically significant (P < .001) relationship between metanephrine levels and SUV with a correlation coefficient of 0.58.
Discussion
18 F-FDG PET/CT scanning is an established technique for tumor staging and follow-up (9) . The findings of the this large prospective study indicate that the usefulness of 18 F-FDG for tumor imaging certainly also pertains to PPGLs. Primary PPGLs are equally well identified by 18 F-FDG PET/CT and 123 I-MIBG SPECT(/CT), currently the standard modality. Metastases are better detected by 18 F-FDG PET than by 123 I-MIBG SPECT, with sensitivities of 80% and 49%, respectively. In fact, one-third of patients with metastatic PPGL had false-negative 123 I-MIBG scans. Moreover, for the localization of metastases of the bone, a frequent site of involvement in malignant PPGL, 18 F-FDG PET, was superior to whole-body CT and/or MRI (sensitivity 94% vs 79%), whereas for soft tissue metastases, the performance was similar.
Regarding the specificity of 18 F-FDG PET, tracer uptake by non-PPGL lesions and by normal adrenal glands might be of concern. This study shows, however, that a very limited number of otherwise unexplained extra-adrenal 18 F-FDG foci were encountered. In most patients, 18 F-FDG uptake by normal adrenal glands did not exceed that of the liver (20) . The distinction between pathological and physiological 18 F-FDG accumulation is facilitated by the calculation of SUV. The diagnosis of adrenal PPGL is highly unlikely when the 18 F-FDG SUV is below 1.1 and very likely when it exceeds 4.6. These cutoffs correspond with 100% sensitivity and specificity, respectively.
Hereditary syndromes are associated with PPGL features such as catecholamine profile, tumor location, and malignant potential (21) . Our current findings and previous observations (11, 22) provide evidence that genotypes also determine the results of functional imaging. For nonmetastatic PPGL, we found that SDH-and VHLrelated tumors are without exception detected by 18 F-FDG PET, whereas the majority of MEN2-related PPGLs are 18 F-FDG PET negative. SUVs were higher for SDH-and VHL-related tumors than for MEN2-and NF1-related tumors. For metastatic PPGL, we confirm that the sensitivity of 18 F-FDG PET is higher in SDHB/D-related than non-SDHB/D-related lesions (8, 11) . Apparently, genotype-specific tumor cell biology translates into distinct patterns of radiotracer uptake and accumulation.
The SDH genes encode the mitochondrial enzyme SDH, which is complex II of the mitochondrial respiratory chain and catalyzes the oxidation of succinate to fumarate in the Krebs cycle. SDH mutations lead to loss of SDH enzymatic activity and induction of hypoxic-and angiogenic-responsive genes (23) . A similar F-FDG PET can be used along with syndromal features, family history, age, tumor location, and catecholamine phenotype (31) to guide the genetic testing strategy in individual patients, prioritizing SDH and VHL testing in those with prominent 18 F-FDG uptake (SUV > 5). For the follow-up of patients with established metastatic PPGL, 18 F-FDG is more sensitive than 123 I-MIBG, especially in patients with SDH-related tumors, and should be performed in addition to CT or MRI to establish the full extent of F-FDG PET is probably less useful for the follow-up of MEN2 and NF1 patients. 18 F-FDG PET also appears to be useful in the localization of HNPGL, but its role among other imaging modalities such as MRI, [ 18 F]-DOPA PET, and somatostatin receptor-based imaging remains to be determined.
One limitation of this study is that a relatively low number of hereditary nonmetastatic PPGLs were available for comparison of genotype-specific imaging results. Further studies with a larger sample size are needed to assess the full impact of the genotypes on 18 F-FDG uptake by PPGL and to establish the role of functional imaging in the diagnosis of underlying hereditary disorders. Also, the usefulness of 18 F-FDG PET for the localization of HNPGL warrants further evaluation with a larger sample size.
In conclusion, 18 F-FDG PET/CT scanning is suitable for routine functional imaging of PPGLs. Compared with 123 I-MIBG SPECT, 18 F-FDG PET allows better detection of metastases, provides a high specificity, and enables functional characterization of PPGL. The observations of a high 18 F-FDG uptake in SDHand VHL-related tumors vs low uptake in MEN2-related tumors illustrate that functional imaging can provide important clues for a hereditary syndrome underlying PPGL.
